<DOC>
	<DOCNO>NCT01590446</DOCNO>
	<brief_summary>The purpose study measure much study drug get blood- stream long take body get rid give single dose . Information side effect may occur also collect .</brief_summary>
	<brief_title>A Study Evaluate Safety Tolerability BMN 111 Administered Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Achondroplasia</mesh_term>
	<criteria>Is willing able provide write , sign inform consent ( legally authorize representative ) nature study explain prior performance researchrelated procedure . Is male 22 45 year age , inclusive Has body weight 63 100 kg , inclusive Has body mass index ( BMI ) 18 32 kg/m2 , inclusive Is able willing abstain nicotine , alcohol , methylxanthinecontaining beverage food ( e.g. , coffee , tea , cola , chocolate , energy drink ) , poppy seed , grapefruit juice 48 hour prior admission duration study Is good health generally , determine medical history , physical examination , clinical laboratory evaluation , 12lead electrocardiogram ( ECG ) Screening Is willing able perform study procedure physically possible If sexually active , willing use condom sexual intercourse female partner female partner use additional effective mean contraception ( e.g. , intrauterine device , coil , diaphragm plus spermicide , oral contraceptive ) abstain sexual intercourse female partner surgically sterile tubal occlusion ( ligation occlude device ) postmenopausal time initial admission research facility last study visit Baseline systolic blood pressure &lt; 100 mmHg Subjects spontaneous orthostatic hypotension , include systolic decline &gt; 20 diastolic change &gt; 10 mmHg heart rate increase &gt; 30 bpm Has renal insufficiency determine eGFR &lt; 65 mL/min/1.73m2 use revise CockcroftGault calculation : ( 140 age [ ] ) body weight [ kg ] / 72 serum creatinine [ mg/dL ] Has anemia ( Hb &lt; 12.5 gm/dL ) Has history cardiac vascular disease , include follow : Congenital heart disease ; Hypertension hypotension ; Cerebrovascular disease ; aortic insufficiency ; Clinically significant atrial ventricular arrhythmia ; Cardiac valvular heart disease ; Hypertrophic cardiomyopathy cardiomyopathy Has Screening ECG show follow : Resting heart rate &lt; 45 &gt; 100 bpm ; PR interval &gt; 210 msec ; P wave duration &gt; 120 msec ; QRS interval &lt; 70 &gt; 120 msec ; Corrected QTc &gt; 440 msec ; QRS axis outside range 30 + 100 degree ; Right leave atrial enlargement ventricular hypertrophy ; Second thirddegree atrioventricular block Heart block intraventricular conduction defect Has diabetes mellitus Type I Type II Is treat angiotensinconverting enzyme inhibitor , antihypertensive medication , diuretic , calciumchannel blocker , betablockers , cardiac glycoside , systemic anticholinergic agent , drug may impair enhance compensatory tachycardia Is treated growth hormone , insulinlike growth factor 1 ( IGF1 ) , anabolic steroid . Has acute illness associate volume dehydration ( e.g. , nausea/vomiting/diarrhea ) . Uses prescription medication , overthecounter medication , nutritional supplement within 10 day prior dose . Uses investigational product investigational medical device within 90 day prior screen require investigational agent prior completion schedule study assessment . Consumes least 14 units/week alcohol ( 1 unit approximate 360 mL beer , 100 mL wine , 35 mL spirit ) significant history alcoholism drug/chemical abuse determine Investigator . Has donate &gt; 50 mL blood plasma within 60 day prior study treatment administration . Has positive urine drug screen alcohol breath test result Screening upon admission research facility . Has use nicotine tobaccocontaining product ( snuff , chew tobacco , cigarette , cigar , pipe , nicotine replacement ) within 90 day first dose study treatment confirm urine cotinine screen . Has positive cotinine test result Screening upon admission research facility . Has history clinically significant neurological , gastrointestinal , renal , hepatic , cardiovascular , psychiatric , respiratory , metabolic , endocrine , hematological , major disorder determine Investigator . Has clinically significant illness within 4 week administration first dose study treatment determine Investigator . Is treated concomitant medication prolongs QT/QTc interval within 7 day 3 halflives , whichever longer , prior Screening Visit . Has AST ALT great 3xULN total bilirubin great 2xULN . Has know hypersensitivity BMN 111 excipients . Has partner plan become pregnant time study . Has condition , view Investigator , place subject high risk poor treatment compliance complete study .</criteria>
	<gender>Male</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Achondroplasia</keyword>
</DOC>